arrow
G

Gregory B. Lesinski

winship cancer institute of emory university
H指数:52
被引数:8,272

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial

新辅助pepinemab联合纳武利尤单抗和/或伊匹木单抗治疗可切除转移性黑色素瘤:一项生物标志物驱动的探索性试验

2026-10-060
OA
A Phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling

一项XL888(HSP90抑制剂)与pembrolizumab联合治疗转移性胰腺癌的Phase Ib/II临床试验,并进行转化性免疫谱分析

2025-12-230
OAAI
Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

过继转输的Th17细胞与宿主B细胞协同作用,以实现持久的肿瘤免疫。

2025-07-240
OAAI
Combination radiation and αPD-L1 enhance tumor control by stimulating CD8+PD-1+TCF-1+T cells in the tumor-draining lymph node

联合放疗和αPD-L1通过刺激肿瘤引流淋巴结中的CD8+PD-1+TCF-1+T细胞来增强肿瘤控制。

2025-04-140
OA
Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine

使用帕立骨化醇和羟氯喹增强胰腺导管腺癌化疗疗效的机制

2025-01-012
OAAI
Phase Ib study of siltuximab and spartalizumab in advanced pancreatic cancer

siltuximab和spartalizumab治疗晚期胰腺癌的Ib期研究

2024-04-050
PRE
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)
2023-07-203
OAAI